$GHXI

Gores Holdings XI, Inc. Announces Pricing of $312 Million Initial Public Offering

Gores Holdings XI, Inc., a Gores Group affiliate-backed blank-check company, priced its IPO of 31.2 million units at $10.00 each, raising $312 million. Units trade on Nasdaq starting June 23, 2026 as GHXIU; each unit includes one Class A share and 1/4 warrant. Santander is sole underwriter; a 45-day option allows up to 4.68 million more units.

Original reporting
Published Jun 23, 2026, 4:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 23, 2026, 4:46 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Gores Holdings XI, Inc. Announces Pricing of $312 Million Initial Public Offering — source image
Decision brief

The 30-second read

$GHXIBullishMed
01

Why it matters

The key tradable development is the priced IPO and the start of trading for the Class A shares (GHXI) and warrants (GHXIW) once separate trading begins, which can drive short-term volatility and positioning.

02

Market read

IPO pricing and the expected Nasdaq tickers for shares/warrants are immediate catalysts for order-flow and first-trading positioning in GHXI/GHXIW.

03

What to watch

Over-allotment option (45 days, +4.68M units) can extend supply/demand dynamics beyond the initial print, affecting near-term trading behavior.

Relevance 8/10Novelty 8/10Timing: begins trading June 23, 2026 after IPO pricing

Background

Gores Holdings XI is a blank-check company formed to pursue a future business combination; this release announces IPO unit pricing and expected Nasdaq symbols for shares and warrants.

Company-level read

Ticker impact

$GHXIBullishMedium confidence
Context

Gores Holdings XI priced its IPO at $10.00 per unit, with Class A shares expected to trade on Nasdaq under GHXI starting June 23, 2026.

Expected impact

Likely initial volatility around first trading and warrant separation; direction depends on demand versus unit price.

Evidence & confidence

The article discloses a concrete capital-markets event (IPO pricing) and the exact expected trading symbols, which can drive short-term order-flow and sentiment.

Market effects

Adds another SPAC/blank-check-style listing to the market, which can marginally affect sentiment toward de-SPAC/blank-check issuance risk.

Primarily US Nasdaq microstructure impact; limited broader regional spillover.

Low global relevance beyond capital-markets sentiment for IPO/blank-check issuance.

Counterpoint

IPO pricing at $10.00 may still be viewed as valuation-neutral; if warrant economics are unattractive, first-day trading could fade.

Key entities

  • Gores Holdings XI, Inc.

    Blank-check company that priced a $312M IPO of 31.2M units at $10.00 per unit.

  • Santander US Capital Markets LLC

    Sole underwriter for the IPO and over-allotment option.

  • SEC

    Registration statement declared effective June 22, 2026.

Related articles

$HOODMed

Robinhood’s new venture fund comes with a bold risk label

Robinhood is launching Robinhood Ventures Fund II (ticker RVII), a business development company offering 8 million shares at $25 each starting Aug. 13. The fund plans to raise $200 million, led by Goldman Sachs. It invests in Y Combinator-linked seed startups and charges a 2% management fee plus a 20% incentive fee, with estimated annual expenses of 4.18%. The prospectus labels the offering speculative and warns of potential discounts to net asset value.

$BRVEMedAI 8/10

Braveheart Bio closes $439.9 million IPO on Nasdaq

Braveheart Bio, Inc. (NASDAQ:BRVE) completed its IPO, selling 24,437,500 shares at $18.00 each, according to a company press release. The offering raised $439.9 million in gross proceeds, including full exercise of an option for 3,187,500 extra shares. Shares began trading on the Nasdaq Global Market under BRVE.

$BRVEMedAI 8/10

Braveheart Bio raises $439.9M in upsized Nasdaq IPO

Braveheart Bio, Inc. (Nasdaq: BRVE) upsized its Nasdaq IPO, selling 24,437,500 shares at $18.00 each, including underwriters’ full option for 3,187,500 shares, for gross proceeds of $439.9 million, per the company. Shares began trading Aug. 6, 2026. The lead candidate is BHB-1893 for hypertrophic cardiomyopathy.